SHEZF (Shenzhen Hepalink Pharmaceutical Group Co) PB Ratio: 0.39 (As of Jul. 13, 2026) — 82% Below Median


SHEZF Shenzhen Hepalink Pharmaceutical Group Co Ltd SHEZF
69 GF Score
Price $0.47
GF Value $0.56
! 7 Warning Signs
View Full Analysis

What is Shenzhen Hepalink Pharmaceutical Group Co PB Ratio?

Shenzhen Hepalink Pharmaceutical Group Co SHEZF 69 PB Ratio is 0.39 as of Jul. 13, 2026, which is 82% below its 10-year median of 2.11. GuruFocus rates SHEZF with a GF Score™ of 69/100 and a GF Value™ of $0.56. The stock has 7 warning signs investors should review. Among 924 Drug Manufacturers companies, Shenzhen Hepalink Pharmaceutical Group Co ranks better than 70.78% on this metric.

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-13), Shenzhen Hepalink Pharmaceutical Group Co's share price is $0.4696. Shenzhen Hepalink Pharmaceutical Group Co's Book Value per Share for the quarter that ended in Mar. 2026 was $1.20. Hence, Shenzhen Hepalink Pharmaceutical Group Co's PB Ratio of today is 0.39.

Good Sign:

Shenzhen Hepalink Pharmaceutical Group Co Ltd stock PB Ratio (=1.15) is close to 2-year low of 1.04.

The historical rank and industry rank for Shenzhen Hepalink Pharmaceutical Group Co's PB Ratio or its related term are showing as below:

SHEZF' s PB Ratio Range Over the Past 10 Years
Min: 0.94   Med: 2.11   Max: 5.32
Current: 1.15

During the past 13 years, Shenzhen Hepalink Pharmaceutical Group Co's highest PB Ratio was 5.32. The lowest was 0.94. And the median was 2.11.

SHEZF's PB Ratio is ranked better than
70.78% of 924 companies
in the Drug Manufacturers industry
Industry Median: 1.91 vs SHEZF: 1.15

During the past 12 months, Shenzhen Hepalink Pharmaceutical Group Co's average Book Value Per Share Growth Rate was -0.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -0.80% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 1.00% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 3.80% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Shenzhen Hepalink Pharmaceutical Group Co was 130.80% per year. The lowest was -10.50% per year. And the median was 2.00% per year.

Back to Basics: PB Ratio


Shenzhen Hepalink Pharmaceutical Group Co  (OTCPK:SHEZF) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Shenzhen Hepalink Pharmaceutical Group Co PB Ratio Related Terms


Shenzhen Hepalink Pharmaceutical Group Co PB Ratio Historical Data

* Premium members only.

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shenzhen Hepalink Pharmaceutical Group Co PB Ratio Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.23 0.60 0.63 0.41 0.40

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.41 0.40 0.40 0.39

SHEZF vs ZTS, UTHR: PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Hepalink Pharmaceutical Group Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shenzhen Hepalink Pharmaceutical Group Co PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shenzhen Hepalink Pharmaceutical Group Co's PB Ratio distribution charts can be found below:

* The bar in red indicates where Shenzhen Hepalink Pharmaceutical Group Co's PB Ratio falls into.


SHEZF
69GF Score
Shenzhen Hepalink Pharmaceutical Group Co Ltd SHEZF
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shenzhen Hepalink Pharmaceutical Group Co PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Shenzhen Hepalink Pharmaceutical Group Co's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=0.4696/1.204
=0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Frequently Asked Questions Learn more about PB Ratio →
What does a PB Ratio of 0.39 mean?
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a PB Ratio of 0.39 as of Jul. 13, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Shenzhen Hepalink Pharmaceutical Group Co and its competitors. This is 82% below median its historical median of 2.11. Over the past decade, Shenzhen Hepalink Pharmaceutical Group Co's PB Ratio has ranged from 0.94 to 5.32. According to the industry distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #270 out of 924 companies in the Drug Manufacturers industry, placing it in the top 29.2%.
Is Shenzhen Hepalink Pharmaceutical Group Co's PB Ratio too high?
Shenzhen Hepalink Pharmaceutical Group Co's current PB Ratio of 0.39 is 82% below median its 10-year median of 2.11. Over the past 10 years, this metric has ranged from a low of 0.94 to a high of 5.32. The Drug Manufacturers industry median PB Ratio is 1.91. Shenzhen Hepalink Pharmaceutical Group Co's value of 0.39 is 79.6% below this industry median. Based on the distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #270 out of 924 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shenzhen Hepalink Pharmaceutical Group Co has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Shenzhen Hepalink Pharmaceutical Group Co's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #270 out of 924 companies for PB Ratio. This puts Shenzhen Hepalink Pharmaceutical Group Co in the upper half of its industry. The industry median PB Ratio is 1.91. Shenzhen Hepalink Pharmaceutical Group Co's value of 0.39 is 79.6% below this benchmark. Historically, Shenzhen Hepalink Pharmaceutical Group Co's own PB Ratio has ranged from 0.94 to 5.32 over the past decade. While the company's 10-year median is 2.11 vs. the industry median of 1.91, Shenzhen Hepalink Pharmaceutical Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.91, based on 924 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhen Hepalink Pharmaceutical Group Co's current PB Ratio of 0.39 is 79.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Shenzhen Hepalink Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen Hepalink Pharmaceutical Group Co's current PB Ratio is 0.39, which is 82% below median its own 10-year median of 2.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Hepalink Pharmaceutical Group Co stock overvalued right now?
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a current PB Ratio of 0.39. The stock's GF Value™ is $0.56, compared to a current price of $0.47 — trading 16.1% below its estimated fair value. The current PB Ratio is 0.39, which is 82% below median its 10-year median of 2.11 and 79.6% below the Drug Manufacturers industry median of 1.91. Shenzhen Hepalink Pharmaceutical Group Co's overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Shenzhen Hepalink Pharmaceutical Group Co (SHEZF), the current PB Ratio is 0.39 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) Overvalued in 2026?

Based on GuruFocus' analysis, Shenzhen Hepalink Pharmaceutical Group Co stock appears to be undervalued. The current stock price of $0.47 is trading 16.1% below its estimated GF Value™ of $0.56.

Key valuation signals for SHEZF:

  • PB Ratio: 0.39 (82% below median its 10-year median of 2.11)
  • GF Value™: $0.56 vs. price of $0.47 (16.1% below fair value)
  • GF Score™: 69/100 with 7 warning signs
  • Industry Position: 79.6% below the Drug Manufacturers median (#270 of 924)

No single metric tells the full story. See the SHEZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shenzhen Hepalink Pharmaceutical Group Co Business Description

Other Exchanges 09989:Hong Kong002399:China
Address No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company. Along with its subsidiary, it is engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development in Asia, Europe, North America, and Australia, and investment business in Asia and North America. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products; Active pharmaceutical ingredients; CDMO business; and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from Europe and the USA.
69GF Score

Get the complete analysis for SHEZF

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.47
Price
$0.56
GF Value